Dr. Alok Kumar Sharma has over 23 years of experience in manufacturing operations and quality assurance in the pharmaceutical bulk drugs industry. He holds a PhD in Organic Chemistry and has worked in leadership roles at several companies, currently serving as Vice President at Kores India Ltd. He has expertise in production planning, quality management, process optimization, and commissioning new plants and products.
Payload Core Product Line Accelerates ADC Clinical TimelinesMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3ddy1sT
Innovators currently must endure years of development and manufacturing to arrive at the most commonly used cGMP payloads. Explore our core product line for dolastatin and maytansinoid payloads which can get developers to the clinic faster while reducing risk.
Dolastatins are antimitotic peptides which exhibit highly potent cytotoxic effects in cancer cells. Due to their pronounced antitumor effects, dolastatins have demonstrated clinical success as payloads for ADCs. However, innovators still face numerous challenges when developing and manufacturing ADC therapies, leading to increased costs and delayed timelines. Our core product line aims to address these challenges.
DOLCore™ product is a versatile and advanced intermediate that can simplify the synthesis of dolastatin payloads by reducing the number of synthesis steps from 15-20 to four or fewer. The value of DOLCore™ translates to significant savings in development and manufacturing costs driven by risk reduction in payload synthesis and avoidance of supply chain disruption.
In this webinar, you will learn about:
• Advantages of dolastatin over other payloads in ADC therapies
• Proprietary DOLCore™ and MayCore™ products
• Flexibility to make new or established dolastatins
• Rapid synthesis technology accelerating the path to drug commercialization
• Seamless supply chain with reduced complexity and regulatory support
Presented by: David Goeddel, Ph.D., Director of API R&D
Single-Use Tangential Flow Filtration for Closed ProcessingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3b7vD60
Closed processing involves use of physical barriers to separate processing fluid from the external environment. This approach reduces capital expenditures and clean room classification while accelerating time to market. This webinar will present a TFF process run in a closed mode.
Closed processing with single-use technologies is a critical enabler for efficient and robust manufacturing for novel modalities as well as continuous biomanufacturing processing. It can also reduce the dependence on classified clean rooms for traditional modalities. This approach helps to mitigate the risk of contamination by adventitious agents while enhancing operator safety.
In this presentation, we discuss the implementation of closed processing for downstream applications and present the design and performance testing of a single use manufacturing-scale tangential flow filtration system to be able to operate in both functionally and fully closed mode.
In this webinar, you will learn:
• The context of closed processing
• Differences between closed and functionally closed processing
• The drivers for adoption
• Its practical implementation to a TFF step
PVA for sustained release: theory and practiceMilliporeSigma
Watch this webinar here: https://bit.ly/32cbiHt
This webinar will introduce PVA as an optimized excipient for sustained release formulations. Combining direct-compression compatibility with a robust and reliable matrix formation, PVA has the potential to enhance sustained release formulations.
By modifying the drug release characteristics, significant therapeutic benefits can be achieved, such as improved efficacy of the therapeutic agent, reduced adverse effects, optimization of the dosing scheme and overall improvement in patient compliance. There are numerous approaches for modified release, each with its own benefits and drawbacks. This webinar will present PVA, a fully-synthetic polymer, for optimized sustained release matrix formulations. Combining robust and reliable gel-forming behavior with optimized tableting properties, PVA provides solutions for the most challenging sustained release formulations.
In this webinar, you will learn:
• How the gel-formation properties of PVA introduce sustained release
• Why compatibility with direct compression leads to simplified formulations
• That PVA can provide flexibility in sustained release formulation development
Payload Core Product Line Accelerates ADC Clinical TimelinesMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3ddy1sT
Innovators currently must endure years of development and manufacturing to arrive at the most commonly used cGMP payloads. Explore our core product line for dolastatin and maytansinoid payloads which can get developers to the clinic faster while reducing risk.
Dolastatins are antimitotic peptides which exhibit highly potent cytotoxic effects in cancer cells. Due to their pronounced antitumor effects, dolastatins have demonstrated clinical success as payloads for ADCs. However, innovators still face numerous challenges when developing and manufacturing ADC therapies, leading to increased costs and delayed timelines. Our core product line aims to address these challenges.
DOLCore™ product is a versatile and advanced intermediate that can simplify the synthesis of dolastatin payloads by reducing the number of synthesis steps from 15-20 to four or fewer. The value of DOLCore™ translates to significant savings in development and manufacturing costs driven by risk reduction in payload synthesis and avoidance of supply chain disruption.
In this webinar, you will learn about:
• Advantages of dolastatin over other payloads in ADC therapies
• Proprietary DOLCore™ and MayCore™ products
• Flexibility to make new or established dolastatins
• Rapid synthesis technology accelerating the path to drug commercialization
• Seamless supply chain with reduced complexity and regulatory support
Presented by: David Goeddel, Ph.D., Director of API R&D
Single-Use Tangential Flow Filtration for Closed ProcessingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3b7vD60
Closed processing involves use of physical barriers to separate processing fluid from the external environment. This approach reduces capital expenditures and clean room classification while accelerating time to market. This webinar will present a TFF process run in a closed mode.
Closed processing with single-use technologies is a critical enabler for efficient and robust manufacturing for novel modalities as well as continuous biomanufacturing processing. It can also reduce the dependence on classified clean rooms for traditional modalities. This approach helps to mitigate the risk of contamination by adventitious agents while enhancing operator safety.
In this presentation, we discuss the implementation of closed processing for downstream applications and present the design and performance testing of a single use manufacturing-scale tangential flow filtration system to be able to operate in both functionally and fully closed mode.
In this webinar, you will learn:
• The context of closed processing
• Differences between closed and functionally closed processing
• The drivers for adoption
• Its practical implementation to a TFF step
PVA for sustained release: theory and practiceMilliporeSigma
Watch this webinar here: https://bit.ly/32cbiHt
This webinar will introduce PVA as an optimized excipient for sustained release formulations. Combining direct-compression compatibility with a robust and reliable matrix formation, PVA has the potential to enhance sustained release formulations.
By modifying the drug release characteristics, significant therapeutic benefits can be achieved, such as improved efficacy of the therapeutic agent, reduced adverse effects, optimization of the dosing scheme and overall improvement in patient compliance. There are numerous approaches for modified release, each with its own benefits and drawbacks. This webinar will present PVA, a fully-synthetic polymer, for optimized sustained release matrix formulations. Combining robust and reliable gel-forming behavior with optimized tableting properties, PVA provides solutions for the most challenging sustained release formulations.
In this webinar, you will learn:
• How the gel-formation properties of PVA introduce sustained release
• Why compatibility with direct compression leads to simplified formulations
• That PVA can provide flexibility in sustained release formulation development
Introduction, Objective; Significance; General consideration; Pilot plant scale up technique for solid, liquid and semi solids; SUPAC Guidelies; Introduction to platform technology
Generic product development and technology transfer : At a glanceDr. Girish S Sonar
It’s honor to get invited as a speaker and to address “Pharma Formulation and Regulatory Symposium” organized by Merck Malaysia on 6th Sept, 2018 at Pullman Bangsar, Kuala Lumpur, Malaysia. The topic I presented was “Generic Product Development and Technology Transfer: At a Glance”. Scientists and industry experts from 31 Malaysia Pharma companies and Universities attended this symposium. The presentation covered challenges and remedies come across from product development to approval from regulatory agencies.
Pleasured to share desk with Dr. Torsten Schadendorf, Marketing Manager Merck Germany, Dr. Gudrun Birk, Head of Controlled Release, Merck Germany and Professor Tin Wui Wong, Universiti Teknologi MARA, Malaysia.
Don’t Feed the Trolls – Crazy Powders and Electrostatic Charge in Continuous ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3to7vDj
Shifting pharmaceutical manufacturing of solid dosage forms from batch to continuous, feeding of excipients and API has gained significant relevance. New critical material attributes determine accurate and consistent performance. For stable long-term operation, understanding of risks for material adhesion is key.
Powder feeding is crucial for a robust continuous manufacturing (CM) operation and product quality. Even with modern gravimetric feeders, this can be a crossroad for CM as different powders interact distinctively with a given equipment. Due to the complex nature of powders, their behavior needs to be considered in a multivariate manner.
We will identify sources of feeding problems, present a set of experiments with a wide range of excipient powders and extract critical material attributes for successful feeding. We will show how feeding may alter powders, and specifically their electrostatic charge. Finally, we will present the effect of relative humidity (RH) on charge and related powder adhesion.
In this webinar, you will learn:
• Why feeding is highly relevant for continuous manufacturing
• How powder properties affect feeding performance
• Which feeding-induced alterations to powder properties may occur
• How relative humidity affects electrostatic charging and material adhesion
Pilot Plant Scale Up Techniques Used in Pharmaceutical Manufacturing, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgaum/Belagavi
When Coating runs smoothly: Enhance your Coating Process with a new Particle ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3bJypPv
Tablet coating simplified. Finding the perfect coating for your formulation can be challenging. A particle engineered polyvinyl alcohol helps you to optimize your process while maintaining full flexibility in designing the right coating formulation at the right time.
In film coating applications water soluble polymers like polyvinyl alcohol (PVA) take a unique position. PVA can be used in immediate release coatings and provides an exceptional moisture and oxygen barrier. A dedicated particle design allows rapid dissolving times and due to the low viscosities of PVA solutions high solid contents can be obtained leading to a high process efficacy.
The webinar will cover coating formulation development as well as novel technologies for characterization of coated tablets that can easily be implemented during production. Optical coherence technology (OCT) and laser scanning microscopy (LSM) can be valuable tools to assess the coating quality.
In this webinar, you will learn:
• How to create your coating formulation by utilizing a broad excipient toolbox
• Potential advantages of PVA as a stable moisture and oxygen barrier to protect challenging drug substances
• Creating the perfect surface finishing
• How to utilize novel analytical technologies to boost your formulation development
A qualified Diploma in chemical Technology 16.5 years of experience in Batch production processes, Industrial Plant Operations, Production Management with Documentation in the Pharmaceutical industries.(Anti-cardiotic drugs, Anti-dandruff drugs, Antibiotic drugs), Food Manufacturing (Nutrition’s)
Introduction, Objective; Significance; General consideration; Pilot plant scale up technique for solid, liquid and semi solids; SUPAC Guidelies; Introduction to platform technology
Generic product development and technology transfer : At a glanceDr. Girish S Sonar
It’s honor to get invited as a speaker and to address “Pharma Formulation and Regulatory Symposium” organized by Merck Malaysia on 6th Sept, 2018 at Pullman Bangsar, Kuala Lumpur, Malaysia. The topic I presented was “Generic Product Development and Technology Transfer: At a Glance”. Scientists and industry experts from 31 Malaysia Pharma companies and Universities attended this symposium. The presentation covered challenges and remedies come across from product development to approval from regulatory agencies.
Pleasured to share desk with Dr. Torsten Schadendorf, Marketing Manager Merck Germany, Dr. Gudrun Birk, Head of Controlled Release, Merck Germany and Professor Tin Wui Wong, Universiti Teknologi MARA, Malaysia.
Don’t Feed the Trolls – Crazy Powders and Electrostatic Charge in Continuous ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3to7vDj
Shifting pharmaceutical manufacturing of solid dosage forms from batch to continuous, feeding of excipients and API has gained significant relevance. New critical material attributes determine accurate and consistent performance. For stable long-term operation, understanding of risks for material adhesion is key.
Powder feeding is crucial for a robust continuous manufacturing (CM) operation and product quality. Even with modern gravimetric feeders, this can be a crossroad for CM as different powders interact distinctively with a given equipment. Due to the complex nature of powders, their behavior needs to be considered in a multivariate manner.
We will identify sources of feeding problems, present a set of experiments with a wide range of excipient powders and extract critical material attributes for successful feeding. We will show how feeding may alter powders, and specifically their electrostatic charge. Finally, we will present the effect of relative humidity (RH) on charge and related powder adhesion.
In this webinar, you will learn:
• Why feeding is highly relevant for continuous manufacturing
• How powder properties affect feeding performance
• Which feeding-induced alterations to powder properties may occur
• How relative humidity affects electrostatic charging and material adhesion
Pilot Plant Scale Up Techniques Used in Pharmaceutical Manufacturing, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgaum/Belagavi
When Coating runs smoothly: Enhance your Coating Process with a new Particle ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3bJypPv
Tablet coating simplified. Finding the perfect coating for your formulation can be challenging. A particle engineered polyvinyl alcohol helps you to optimize your process while maintaining full flexibility in designing the right coating formulation at the right time.
In film coating applications water soluble polymers like polyvinyl alcohol (PVA) take a unique position. PVA can be used in immediate release coatings and provides an exceptional moisture and oxygen barrier. A dedicated particle design allows rapid dissolving times and due to the low viscosities of PVA solutions high solid contents can be obtained leading to a high process efficacy.
The webinar will cover coating formulation development as well as novel technologies for characterization of coated tablets that can easily be implemented during production. Optical coherence technology (OCT) and laser scanning microscopy (LSM) can be valuable tools to assess the coating quality.
In this webinar, you will learn:
• How to create your coating formulation by utilizing a broad excipient toolbox
• Potential advantages of PVA as a stable moisture and oxygen barrier to protect challenging drug substances
• Creating the perfect surface finishing
• How to utilize novel analytical technologies to boost your formulation development
A qualified Diploma in chemical Technology 16.5 years of experience in Batch production processes, Industrial Plant Operations, Production Management with Documentation in the Pharmaceutical industries.(Anti-cardiotic drugs, Anti-dandruff drugs, Antibiotic drugs), Food Manufacturing (Nutrition’s)
A qualified Diploma in chemical Technology 16.5 years of experience in Batch production processes, Industrial Plant Operations, Production Management with Documentation in the Pharmaceutical industries.(Anti-cardiotic drugs, Anti-dandruff drugs, Antibiotic drugs), Food Manufacturing (Nutrition’s)
009 what are the systems validation protocol methods at atl 05 28-2015atlmarketing
If your product must meet the requirements of FDA cGMP, 21 CFR 210, 211, 820, ISO-9000, ISO-13485, or MDD/93/42/EEC (for the CE Mark), there are three very critical elements you must have to be in regulatory compliance. First, you must have a sound and strong Quality Management System (QMS). This is an expression of WHAT you do (your quality policies and structure). Second, you must have reliable Standard Operating Procedures (SOP’s). These are expressions of HOW YOU DO THINGS.
Missing in the above two items is an expression of HOW WELL YOU DO WHAT YOU DO? This is where you must establish your “Systems Validation Protocol” (SVP). Your SVP is an expression of how well your system is working (for example, this can be expressed in overall product conformance percentage or in defects per million for your various products). The SVP is a living and continuous document based on your quality records. The ATL White Paper “What Are The Systems Validation Protocol Methods At ATL?” is our attempt to share with you a sound approach to Systems Validation and the various protocols that you can use.
pilot plant is a small system which is operated to find out about the behavior of a process before using it on a large industrial scale. so, this presentation tries to illustrate its objective and significance to understand the methodologies of various pharmaceutical dosage forms.
1. DR. ALOK KUMAR SHARMA
E-2103, Sunflower,Neelkanth Greens,Manpada Ghodbunder Road,
Thane-400610, Maharashtra
Ph: +919819691657
Email: alok18_sharma@rediffmail.com, alokalpana2004@yahoo.co.uk,
I am Eligible for senior management positions in Manufacturing Operations/ Quality Assurance
with a progressive organization of repute, preferably in Pharma Bulk Drugs Industry.
Educational details
Examination Year Main Subjects Division
Secondary school examination 1975-76 Physics, chemistry &
Maths
First (Distinction in
chemistry)
Higher secondary school
examination
1976-77 Physics, chemistry &
Maths
First ((Distinction in
chemistry)
B.Sc( Three years degree ) 1977-1980 Physics, chemistry &
Maths
First
M.Sc ( Organic chemistry) 1980 to 1983 Organic chemistry
(Specialisation)
First division ( Stood 4th
in
university )
Ph.D (Organic chemistry) 1983 to 1988 Topic: Thiophene and
sesquiterpenoids,
isolation
characterisation and
synthesis of some
derivatives
Degree was awarded in
1988 after examination of
thesis and interview by one
of the top scientist of India
Dr.Nityanand ( Director of
Central drug research
Institute)
PG diploma in RA(API) 2015-16 ICH,CTD,Impurities,
stability,EU and US
submissions,AVM,etc
73%
PROFESSIONAL PROFILE
PhD in Organic Chemistry with over 23 years rich experience in production, plant operations,
process improvements, quality control in pharma / bulk drugs industry.
GSK -1989 to 2003
Hands On experience of running a plant ( 200 reactors), Compliance with cGMP and group policies
and procedures, Process optimisation, commissioning of new products, commissioning of new plants
, Establishing quality systems with QA and implementation, cost reduction, MIS reporting ,
secretary of technical committee of the technical operations of the site,HAZOP, Risk analysis ,
training validations SOP writing etc, In absence of factory manager , coordinating the activity of
the factory.
A keen planner with profound expertise in developing and effectuating production & quality
plans, providing quality guidelines for achieving top-level performance levels.
Proven ability of spearheading capacity enhancement projects; achieving significant cost
reduction.
Keen understanding of safety and GMP aspects.
Demonstrated competence of setting up processes for commencement of Clobetasol,
Clobetasone and Beclomethasone production.
Experience of handling production of bulk drugs such as:
Vitamin A,
Trichlor Phos,
Calcium Sennosides,
3. Played a key role in exalting capacity levels of the following:
- Betamethasone plant by from 1800 kg per annum to 2650 kg per annum and further
balancing capacity to 3.5T per annum. This capacity expansion saved a lot of expenditure.
Recycled recovered solvent at a quality critical stage, thus saving costs.
Reduced usage of high value catalyst which brought down the cost substantially.
Pivotal in handling removal of foreign impurities from finished API through location of cause of
physical contamination.
Single handedly completed Perfect Supply Model Project, which involved comparison of
company business with that of competitors in terms of quality, compliances, costs, safety
measures etc.
Spearheaded commissioning of Clobetasol, Clobetasone and Beclomethasone processes at
commercial level.
Achieved significant cost reduction through reuse quality critical solvents in Betamethasone and
also reduced occurrence of hazards.
Process validation of 21 stage chemical synthesis.
Written technical packages for various products and processes.
Technology transfer/ receiving.
Trouble shooting.
Norbrook : 2003 t0 2004
• Capacity expansion of one of the API
• Commissioning and operation of computer controlled solvent recovery plant
Saurav chemicals :2005
• Commencing the commercial production
• Solving the technical problems of hydrogenation reaction of sertaline hydrochloride
process.
• Qualification process of equipment including HVAC
• Writing SOP’s and implementing quality systems.
Sdfine chemicals :2006
• DQ/IQ/OQ of facility
• Qualification of SCADA system and documentation.
• Developing and optimising some of the molecules for other parties (process development)
• Documentation system for the facility (Operating procedure)
• Plant administration
• Chairman of safety committee.
• Technical discussions with consultants and the plant engineers and implementation of
the project related activity
• Regular production activity (although the plant was not fully loaded)
GULF Oil corporation(WHO certified(2007 to2009)
• cephalosporin production
• Capacity planning
• COS for EDQM
• Responsible for factory’s commercial production and administration
• Recently factory has been inspected for WHO-GMP
• Process of quality management system implementation is on now.
• Currently engaged in stabilising the new products and technical aspects of the process.
• Just started the cleaning validation master plan and work is going on.
• Cleaning validation master plan
4. Biocon Ltd: Head of operations.(2009 to 2010)
• Setting –up the factory
• Recruitment and coordination with Statutory bodies
• Responsible for Factory P&L
• Responsible for product commissioning and commercial production.
Kores India Ltd.(2010 to present)
Currently I am working as vice president with Kores India Ltd. The business involves APIs and
advanced intermediates.
Current Organogram
1. 20 million USD
2. 250 employees
3. Technical and commercial operations of the division.
4. International customers (Recordeti, Cambrex, Sifavitor, Nycomed, Perkin Elmer
(Netherlands),Donghawa (Korea), ABC pharmaceuticals-Italy),BASF, AMSA, Chemicia
Fabrik (Germany), Euticals.
5. Domestic Customers: Hetero drugs, Zudus Cadilla, Cipla,Abott
Responsible for Divisional P&L.
BROAD PERFORMANCE AREAS
Quality Assurance
o Appraising the prevalent production systems/ processes, identifying loopholes if any and
undertaking result-oriented measures for alleviating them.
o Coordinating with customers for attending to their technical/ product related issues.
o Implementing steps for curtailing product/ process rejections and defects.
o Self audit and suppliers audit
o Gap analysis and action planning.
o GMP training to the staff.
o Validation
• Qualification of equipment
• Qualification of SCADA /PLC system
• Qualification of water system
• SOP writing
• BMR preparation
• Review of completed BMR’s
• Cleaning validation
KPI’s
Production volumes and factory financial targets
ALOK
R&D Finance PurchaseFactory Marketing
5. Statutory compliances
Perfect supply
Health and safety
Best in Class cost
Responsive supply
IR
Quality and improvement related projects
Investigation of failures and salvaging the batches
Giving the procedures for rework
Trouble shooting in the process
Product development
Commissioning of the processes in the plant
Manufacturing/ Plant Operations
o Developing plans/ schedules for producing bulk drugs keeping in consideration procedural and
quality norms.
o Budgeting of the production for the year.
o Ascertaining resource requirements, making proper arrangement of the same to prevent
disruption of manufacturing operations at any stage.
o Establishing processes/ systems, focussing on optimisation parameters.
o Ensuring minimal machine breakdowns to curtailing machine downtime.
o Implementing good manufacturing practices for enhancing product yield and curtailing
expenses.
o Commissioning of the new processes and plant
o Implementing safe working practices by following laid down policies.
o Trouble shooting and rework procedure for salvaging the batches.
New Improvement Initiatives
o Commencing new product development functions as per the current market trends.
o Effectuating high-value added systems/ procedures to speed up production and exalt
output.
o Devising measures for exalting plant capacity utilization, product yield and quality.
o Commissioning of equipment and new products
o Failure investigation
o SOP preparation
Team Management
o Providing safety/ GMP training to subordinates to enhance awareness/ performance levels.
o Mentoring and motivating subordinates for exalting their competency skills.
Supply Chain Management
• Customer service
• Rough cut capacity planning
• Inventory control (WIP&RO + raw materials)
• Liasoning with customer and suppliers
• Production Planning
Health and safety
• Training
• Audits and spot checks
• Hazop studies
• Risk analysis
• Accident and dangerous occurrence analysis
• Chairing the safety meetings
• COSHH analysis and action planning
6. TRAINING PROGRAMMES ATTENDED
- Finance for non- finance persons - General Management Course
- Target setting - Plant and Operational Safety
- GMP Training - Action based safety
- TQM/ Lean Sigma
IT SKILLS: MS Office and MS Project
DATE OF BIRTH: 18th
August 1961.
7. TRAINING PROGRAMMES ATTENDED
- Finance for non- finance persons - General Management Course
- Target setting - Plant and Operational Safety
- GMP Training - Action based safety
- TQM/ Lean Sigma
IT SKILLS: MS Office and MS Project
DATE OF BIRTH: 18th
August 1961.